| RRC ID |
52042
|
| 著者 |
Takashima S, Toyoshi K, Itoh T, Kajiwara N, Honda A, Ohba A, Takemoto S, Yoshida S, Shimozawa N.
|
| タイトル |
Detection of unusual very-long-chain fatty acid and ether lipid derivatives in the fibroblasts and plasma of patients with peroxisomal diseases using liquid chromatography-mass spectrometry.
|
| ジャーナル |
Mol Genet Metab
|
| Abstract |
Metabolic changes occur in patients with peroxisomal diseases owing to impairments in the genes involved in peroxisome function. For diagnostic purposes, saturated very-long-chain fatty acids (VLCFAs) such as C24:0 and C26:0, phytanic acid, pristanic acid, and plasmalogens are often measured as metabolic hallmarks. As the direct pathology of peroxisomal disease is yet to be fully elucidated, we sought to explore the fatty acid species that accumulate in patients with peroxisomal diseases. We developed a method for detecting a range of fatty acids implicated in peroxisomal diseases such as Zellweger syndrome (ZS) and X-linked adrenoleukodystrophy (X-ALD). To this end, we employed an ultra-performance liquid chromatography-mass spectrometry (LC-MS) coupled with negatively charged electrospray ionization. Fatty acids from patients and control subjects were extracted from total lipids by acid-hydrolysis and compared. In accordance with previous results, the amounts of VLCFAs, phytanic acid, and pristanic acid differed between the two groups. We identified extremely long and highly polyunsaturated VLCFAs (ultra-VLC-PUFAs) such as C44:12 in ZS samples. Moreover, three unknown molecules were prominent in control samples but scarcely detectable in ZS samples. LC-MS/MS analysis identified these as 1-alkyl-sn-glycerol 3-phosphates derived from ether lipids containing fatty alcohols such as C16:0, C18:0, or C18:1. Our method provides an approach to observing a wide range of lipid-derived fatty acids and related molecules in order to understand the metabolic changes involved in peroxisomal diseases. This technique can therefore be used in identifying metabolic markers and potential clinical targets for future treatment.
|
| 巻・号 |
120(3)
|
| ページ |
255-268
|
| 公開日 |
2017-3-1
|
| DOI |
10.1016/j.ymgme.2016.12.013
|
| PII |
S1096-7192(16)30180-9
|
| PMID |
28089346
|
| MeSH |
Adrenoleukodystrophy / metabolism*
Cells, Cultured
Chromatography, High Pressure Liquid / methods
Ethers / blood
Ethers / metabolism*
Fatty Acids / blood
Fatty Acids / metabolism*
Fibroblasts / cytology
Fibroblasts / metabolism*
Humans
Lipids / blood
Peroxisomal Disorders / metabolism
Spectrometry, Mass, Electrospray Ionization
Tandem Mass Spectrometry / methods
Zellweger Syndrome / metabolism*
|
| IF |
4.17
|
| 引用数 |
7
|
| リソース情報 |
| ヒト・動物細胞 |
NB1RGB(RCB0222) |
